Federally Funded Clinical Trials

Federally Funded Clinical Trials

Our research sites continue to participate in Federally-funded research through NRG Oncology.  The following protocols are currently open to accrual.  Please visit the NRG Oncology website or the CTSU members' website for more information.


Protocol Activation (Date Opened to Accrual): 08/22/2013

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

ClinicalTrials.gov Identifier: NCT01872975


 NRG - BR003

Protocol Activation (Date Opened to Accrual): 06/26/2015

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

ClinicalTrials.gov Identifier: NCT02488967

NRG - BR004

Protocol Activation (Date Opened to Accrual): 03/12/2019

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

ClinicalTrials.gov Identifier: NCT03199885

NRG - BR005

Protocol Activation (Date Opened to Accrual): 04/13/2017

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery

ClinicalTrials.gov Identifier: NCT03188393

NRG - GI002

Protocol Activation (Date Opened to Accrual): 10/12/2016

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

ClinicalTrials.gov Identifier: NCT02921256

NRG - GI004

Protocol Activation (Date Opened to Accrual): 11/7/17

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

ClinicalTrials.gov Identifier: NCT02997228